Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 1 , Pages 19-26 , February 2010

Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas

  • Markus Raderer

      Affiliations

    • Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author.
    • ,
  • Jan Paul de Boer

      Affiliations

    • Netherlands Cancer Institute, Amsterdam, The Netherlands

References 

  1. de Boer J, Hiddink R, Raderer M, Antonini N, Aleman B, Boot H, et al. Dissemination patterns in non-gastric MALT lymphoma. Haematologica. 2008 Feb 1;93(2):201–206
  2. Raderer M, Streubel B, Woehrer S, Puespoek A, Jaeger U, Formanek M, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res. 2005 May 1;11(9):3349–3352
  3. Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995 Oct 1;13(10):2524–2529
  4. Levy M, Copie-Bergman C, Gameiro C, Chaumette M, Delfau-Larue M, Haioun C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005 Aug 1;23(22):5061–5066
  5. Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367–375
  6. Greiner A, Knorr C, Qin Y, Sebald W, Schimpl A, Banchereau J, et al. Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation. Am J Pathol. 1997 May;150(5):1583–1593
  7. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet. 1993 Sep 4;342(8871):571–574
  8. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol. 1996 Feb;178(2):122–127
  9. Hussell T, Isaacson PG, Spencer J. Proliferation and differentiation of tumour cells from B-cell lymphoma of mucosa-associated lymphoid tissue in vitro. J Pathol. 1993 Feb;169(2):221–227
  10. Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann Oncol. 1999 Jun 1;10(6):637–645
  11. Jager G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002 Sep 15;20(18):3872–3877
  12. Jager G, Neumeister P, Quehenberger F, Wohrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol. 2006 Nov;17(11):1722–1723
  13. Germann N, Brienza S, Rotarski M, Emile JF, Di PM, Musset M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol. 1999 Mar;10(3):351–354
  14. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, et al. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer. 2005 Aug 15;104(4):781–787
  15. Raderer M, Wohrer S, Bartsch R, Prager G, Drach J, Hejna M, et al. Phase II Study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2005 Nov 20;23(33):8442–8446
  16. Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, et al. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer. 2001 Nov 2;85(9):1258–1264
  17. Machover D, mas-Marsalet B, Misra SC, Gumus Y, Goldschmidt E, Schilf A, et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol. 2001 Oct;12(10):1439–1443
  18. Aviles A, Nambo MJ, Neri N, Talavera A, Cleto S. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol. 2005;22(1):57–62
  19. Raderer M, Streubel B, Wohrer S, Hafner M, Chott A. Successful antibiotic treatment of helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut. 2006 May 1;55(5):616–618
  20. Wohrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Puspok A, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003 Dec;14(12):1758–1761
  21. Raderer M, Jager G, Brugger S, Puspok A, Fiebiger W, Drach J, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003;65(4):306–310
  22. Conconi A, Martinelli G, Thieblemont C, Ferreri A, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741–2745
  23. Martinelli G, Laszlo D, Ferreri A, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-hodgkin's lymphoma resistant to or not eligible for anti-helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979–1983
  24. Wohrer S, Puspok A, Drach J, Hejna M, Chott A, Raderer M. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol. 2004 Jul 1;15(7):1086–1090
  25. Troch M. Haematologica. 2009 May 1;epub ahead of print
  26. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007 May 2;99(9):706–714
  27. Witzig T. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol. 2005 Sep 10;23(26):6409–6414
  28. Ketterer N, Salles G, Espinouse D, Dumontet C, Neidhardt-Berard EM, Moullet I, et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol. 1997 Jul;8(7):701–704
  29. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, Van Hoof A, Kluin-Nelemans H, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558–565
  30. Huang WT, Hsu YH, Yang SF, Chuang SS. Primary gastrointestinal follicular lymphoma: a clinicopathologic study of 13 cases from Taiwan. J Clin Gastroenterol. 2008 Oct;42(9):997–1002
  31. Damaj G, Verkarre V, Delmer A, Solal-Celigny P, Yakoub-Agha I, Cellier C, et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol. 2003 Apr;14(4):623–629
  32. Marcus R, Imrie K, Solal-Celigny P, Catalano J, Dmoszynska A, Raposo J, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008 Oct 1;26(28):4579–4586
  33. Ferrucci P, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?. Br J Haematol. 2007 Feb 3;136(4):521–538
  34. Koch P, Probst A, Berdel W, Willich N, Reinartz G, Brockmann J, et al. Treatment results in localised primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol. 2005 Oct 1;23(28):7050–7059
  35. Persky D, Unger J, Spier C, Stea B, LeBlanc M, McCarty M, et al. Phase II Study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-Cell lymphoma: southwest oncology group study 0014. J Clin Oncol. 2008 May 10;26(14):2258–2263
  36. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379–391
  37. Raderer M, Chott A, Drach J, Montalban C, Dragosics B, Jager U, et al. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?. Ann Oncol. 2002 Jul;13(7):1094–1098
  38. Aviles A, Castaneda C, Cleto S, Neri N, Huerta-Guzman J, Gonzalez M, et al. Rituximab and chemotherapy in primary gastric lymphoma. Cancer Biother Radiopharm. 2009 Feb;24(1):25–28
  39. Aviles A, Nambo MJ, Neri N, Huerta-Guzman J, Cuadra I, Alvarado I, et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg. 2004;240(1):44–50
  40. Bonnet C, Fillet C, Mounier N, Ganem G, Molina TJ, Thieblemont C, et al. CHOP alone compared with CHOP plus radiotherapy for localised aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adult. J Clin Oncol. 2007;25(7):787–792

PII: S1521-6918(09)00151-6

doi: 10.1016/j.bpg.2009.11.001

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 1 , Pages 19-26 , February 2010

Article Tools